Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825590 | 1.00 | KMT2A (0.54) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL4740872 | 1.00 | KMT2A (0.54) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL22728173 | 0.86 | MEN1 (0.47) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL15745442 | 0.86 | MEN1 (0.53) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL27397174 | 0.86 | MEN1 (0.53) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL5018863 | 0.86 | MEN1 (0.49) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL18261706 | 0.84 | MEN1 (0.58) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL4766420 | 0.83 | MEN1 (0.46) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL7973701 | 0.83 | MEN1 (0.45) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL1262055 | 0.83 | CA12 (0.46) | KMT2AMEN1GAACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| EP-3860657-A1 | SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES | Novartis AG (CH) | 2021-08-11 | — | — | EP | claimed |
| CN-112770782-A | Sustained delivery of angiopoietin-like 3 polypeptides | 诺华股份有限公司 | 2021-05-07 | — | — | CN | claimed |
| WO-2020070675-A1 | SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES | NOVARTIS AG (CH) | 2020-04-09 | — | — | WO | claimed |
| EP-3612233-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | Novartis AG (CH) | 2020-02-26 | — | — | EP | claimed |
| CN-110603060-A | Sustained release delivery system comprising traceless linker | 诺华股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| WO-2018193408-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2018-10-25 | — | — | WO | claimed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| US-4644008-A | Perhydroindole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1987-02-17 | — | — | US | disclosed |
| US-4622232-A | L-aminodicarboxylic acid alkanes | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| US-4616031-A | Perhydroindole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1986-10-07 | — | — | US | disclosed |
| US-4616030-A | Perhydroindole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1986-10-07 | — | — | US | disclosed |
| US-4616029-A | Perhydromdole-2-carboxylic acids as antihypertensives | ADIR (FR) | 1986-10-07 | — | — | US | disclosed |
| US-4565819-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | ADIR (FR) | 1986-01-21 | — | — | US | disclosed |
| US-4508729-A | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | KMT2A 1052/4885MEN1 4664/4885GAA 2026/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | KMT2A 1725/4885MEN1 2713/4885GAA 1634/4885 |
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NOD1, NLRP3, CASP1 | KMT2A 3161/4885MEN1 1374/4885GAA 4644/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | KMT2A 365/4885MEN1 1223/4885GAA 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.